金币
UID176556
帖子
主题
积分25187
注册时间2014-6-6
最后登录1970-1-1
听众
性别保密
|
发表于 2017-11-14 09:21:10
|
显示全部楼层
下面仅仅供参考:
其实针对于中间体的DMF一般是不进行收费的!
https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm319567.htm
Q2. Which DMFs incur fees?
Only DMFs that cover the manufacture of an API (Type II API DMFs) for use in a generic drug application incur fees. Specifically, each person that owns a Type II API DMF (DMF holder) that is referenced on or after October 1, 2012, in a generic drug submission by any initial letter of authorization shall be subject to a DMF fee.
但是需要注意一点的是API的扩展定义:
https://www.morganlewis.com/~/media/files/publication/lawflashclient%20alert/life%20sciences%20and%20healthcare%20lawflash/fda_lf_fdauserfeeact_25july12.ashx
Drug Master File Fees Could Affect Timing of ANDA Filings
As part of GDUFA there are now fees for review of Type II Drug Master Files (DMFs) for active ingredients referenced in ANDAs. The law provides a somewhat expanded definition of “active pharmaceutical ingredient” (API), providing that API also includes “a substance intended for final crystallization, purification or salt formation or any combination of these activities to become the final API.” This expansion may mean that manufacturers of late-stage intermediates will have to pay a facility fee for the intermediate and for the Type II DMF, if applicable.
There are a number of new requirements that accompany the Type II DMF user fees, including the following:
• Each person that owns a Type II DMF that is referenced on or after October 1, 2012, in a generic drug submission by any initial letter of authorization will pay an annual fee.
• In order to be referenced in an ANDA, each Type II DMF holder will need to have paid the user fee and not failed an initial completeness assessment of the DMF as defined by FDA.
• Facilities that produce both active ingredients subject to DMFs and finished dosage forms must pay both user fees.
• FDA intends to list publicly all DMFs that have satisfied an initial completeness assessment and paid the relevant fees.
• DMF fees must be paid no later than the date on which the first generic drug submission is submitted that references the DMF.
|
|